BPX-501
Phase 2Cell therapy
BPX-501 is one of 49 biologic programs targeting Stem Cell Transplant. It is currently in Phase 2.
3
Indications
7
Total Trials
4
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
32 competitors in Stem Cell Transplant
#DrugCompanyPhaseTrials
1Fludara
SanofiPhase 3
Cellcept
RochePhase 3
Alkeran
AApotex Inc.
Phase 3
Busulfex
Akero TherapeuticsPhase 2
Fludara
SanofiPhase 2
Prograf
VVeloxis Pharmaceuticals
Phase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Cytosar
TevaPhase 2
Medrol
PfizerPhase 2
Neupogen
EEastern Cooperative Oncology Group
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Stem Cell Transplant4 trials
Malignancies1 trial
Advanced Hematologic Malignancies1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BPX-501. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 2[1]
- Company
- BBellicum Pharmaceuticals